ITI Pharma and Healthcare Fund vs Nippon India Taiwan Equity Fund
Direct Plan, Growth option · Data as on 30-10-2026
ITI Pharma and Healthcare Fund is a Thematic fund and Nippon India Taiwan Equity Fund is a Thematic fund. In the 3 years to 30-10-2026, ITI Pharma and Healthcare Fund (Direct) returned 20.3% a year and Nippon India Taiwan Equity Fund (Direct) returned 54.8% a year. ITI Pharma and Healthcare Fund charges 0.89% a year and Nippon India Taiwan Equity Fund 1.08% (Direct plans). Their portfolios overlap 0.0%: they hold 0 of the same securities.
ITI Pharma and Healthcare Fund
Thematic
- 3 year return
- 20.3%
- Expense ratio
- 0.89%
- NAV
- ₹19.46
Nippon India Taiwan Equity Fund
Thematic
- 3 year return
- 54.8%
- Expense ratio
- 1.08%
- NAV
- ₹31.86
Which is better, ITI Pharma and Healthcare or Nippon India Taiwan Equity? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Nippon India Taiwan Equity returned more over 3 years: 54.8% a year against 20.3%.
- Nippon India Taiwan Equity returned more over 1 year: 75.7% against 9.4%.
- ITI Pharma and Healthcare costs less: 0.89% a year against 1.08% (Direct plans).
- ITI Pharma and Healthcare swung less over 3 years: a standard deviation of 14.2% a year against 35.3%.
- ITI Pharma and Healthcare fell less in its worst fall since 14-12-2021: −17.7% against −44.8%.
- Nippon India Taiwan Equity holds 90.8% of the fund in foreign stocks; ITI Pharma and Healthcare 0.0%.
- ITI Pharma and Healthcare holds more in large companies: 35.9% of the fund in large caps against 0.0%.
- Nippon India Taiwan Equity is the larger fund: ₹1,147 Cr against ₹266 Cr.
- Their portfolios overlap 0.0%: 0 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | ITI Pharma and Healthcare Fund | Nippon India Taiwan Equity Fund |
|---|---|---|
| Fund house | ITI Mutual Fund | Nippon India Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹266 Cr (30-09-2026) | ₹1,147 Cr (30-09-2026) |
| NAV | ₹19.46 (Direct) | ₹31.86 (Direct) |
| Expense ratio (Direct) | 0.89% | 1.08% |
| Expense ratio (Regular) | 2.59% | 2.36% |
| Riskometer | Very High | Very High |
| Benchmark | NIFTY Healthcare TRI | Taiwan Capitalization Weighted Stock Index (TAIEX) |
| Launch date | 08-11-2021 | 11-12-2021 |
| Minimum investment | ₹5,000 | 500; Note - Lumpsum subscription under the Scheme is suspended temporarily with effect from February 26, 2024 |
| Lock in | None | None |
| Fund managers | Animesh Singh, Nilay Dalal | Kinjal Desai |
| Exit load | Exit load of 0.50%, if redeemed within 3 months. | 1% if redeemed or switched out on or before completion of 3 months from the date of allotment of units. Nil, thereafter |
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 0.00% | −1.04% | +11.74% | +9.43% | +20.30% | -- | -- |
| Nippon India Taiwan Equity Fund (Direct) | −16.05% | +11.27% | −9.87% | +75.71% | +54.78% | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
Category average: the average of the 235 Thematic funds, same plan type.
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Year-wise Returns
| Year | ITI Pharma and HealthcareITI Pharma and Healthcare | Nippon India Taiwan EquityNippon India Taiwan Equity |
|---|---|---|
| 2026to date | +14.07% | +66.72% |
| 2025 | −8.24% | +52.84% |
| 2024 | +43.95% | +25.96% |
| 2023 | +34.39% | +46.55% |
| 2022 | −6.68% | −33.29% |
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Rolling Returns
Every holding period of both funds, against Nifty Healthcare Index TRI, the benchmark of ITI Pharma and Healthcare Fund
Rolling returns
Every 3-year holding period, 462 of them, one for each trading day from 16-12-2024 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Taiwan Equity Fund (Direct)
Nifty Healthcare Index TRI
to
Feb 2025Jun 2022
to
Jun 2025Sept 2022
to
Sept 2025Jan 2023
to
Jan 2026May 2023
to
May 2026Sept 2023
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare | 0.0 | 0.0 | 0.0 | 0.0 | 14.7 | 78.8 | 6.5 | 21.7% | 21.4% | 17.3% | 26.9% | 47% |
| Nippon India Taiwan Equity | 0.5 | 2.5 | 13.1 | 9.0 | 1.6 | 3.5 | 69.8 | 36.8% | 38.9% | −3.0% | 69.5% | 72% |
| Nifty Healthcare Index TRI | 0.0 | 0.0 | 0.0 | 0.0 | 21.2 | 71.0 | 7.8 | 21.9% | 22.3% | 15.6% | 27.3% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty Healthcare Index TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 14-12-2021. Past returns do not promise future returns.
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-12-2021 to 30-10-2026: 59 instalments, ₹5,90,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct) | ₹5,90,000 | ₹8,88,027 | ₹2,98,027 | 16.7% |
| Nippon India Taiwan EquityNippon India Taiwan Equity Fund (Direct) | ₹5,90,000 | ₹17,24,248 | ₹11,34,248 | 45.5% |
ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct)
Nippon India Taiwan EquityNippon India Taiwan Equity Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Taiwan Equity Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.43% | +75.71% |
| Standard deviation | 13.63% | 40.75% |
| Sharpe ratio | 0.31 | 1.73 |
| Sortino ratio | 0.44 | 2.48 |
| Maximum drawdown | −11.7% (29-01-2026) | −29.6% (30-07-2026) |
| Beta | 0.91 | -- |
| Alpha | −1.48% | -- |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Taiwan Equity Fund (Direct) |
|---|---|---|
| Return (CAGR) | +20.30% | +54.78% |
| Standard deviation | 14.17% | 35.27% |
| Sharpe ratio | 1.01 | 1.38 |
| Sortino ratio | 1.41 | 2.03 |
| Maximum drawdown | −17.1% (03-03-2025) | −37.6% (09-04-2025) |
| Beta | 0.90 | -- |
| Alpha | +0.31% | -- |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Taiwan Equity Fund (Direct) |
|---|---|---|
| Return (CAGR) | +14.34% | +27.46% |
| Standard deviation | 13.44% | 32.62% |
| Sharpe ratio | 0.63 | 0.66 |
| Sortino ratio | 0.89 | 0.95 |
| Maximum drawdown | −17.7% (17-06-2022) | −44.8% (25-10-2022) |
| Beta | 0.84 | -- |
| Alpha | +1.08% | -- |
From daily NAVs, 11-11-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Taiwan Equity Fund (Direct)
Nifty Healthcare Index TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | −17.7% | 13-01-2022 | 17-06-2022 | 16-06-2023 | 12 months | −4.2% |
| Nippon India Taiwan Equity Fund (Direct) | −44.8% | 04-01-2022 | 25-10-2022 | 23-01-2024 | 15 months | −21.7% |
| Nifty Healthcare Index TRI | −18.3% | 31-12-2021 | 17-06-2022 | 30-06-2023 | 12 months | −2.9% |
From daily values since 14-12-2021, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Taiwan Equity Fund (Direct)
Nifty Healthcare Index TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Taiwan Equity Fund (Direct)
Nifty Healthcare Index TRI
Against Nifty Healthcare Index TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 93% | 87% | 5.04% |
| Nippon India Taiwan Equity Fund (Direct) | 65% | -55% | 37.51% |
From month-end values since 14-12-2021. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Portfolio Overlap
From each fund's latest monthly portfolio: ITI Pharma and Healthcare Fund, September 2026; Nippon India Taiwan Equity Fund, September 2026
Holdings in common
- Overlap
- 0.0%
- Held by both
- 0
- Only in ITI Pharma and Healthcare
- 37
- Only in Nippon India Taiwan Equity
- 0
Overlap: for each holding both funds own, the smaller of its two weights, added up. 0.0% means 0.0% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in ITI Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Sun Pharmaceutical Industries Limited | 11.96% |
| Divi's Laboratories Limited | 9.51% |
| Apollo Hospitals Enterprise Limited | 5.45% |
| Torrent Pharmaceuticals Limited | 4.78% |
| Dr. Reddy's Laboratories Limited | 4.78% |
Largest holdings only in Nippon India Taiwan Equity Fund
Every holding of this fund is also held by the other.
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | ITI Pharma and Healthcare | Nippon India Taiwan Equity |
|---|---|---|
| Equity | 99.3% | 90.8% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.7% | 9.2% |
Market cap of stocks
| Market cap | ITI Pharma and Healthcare | Nippon India Taiwan Equity |
|---|---|---|
| Large Cap | 35.9% | 0.0% |
| Mid Cap | 40.5% | 0.0% |
| Small Cap | 23.0% | 0.0% |
| Foreign stocks | 0.0% | 90.8% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | ITI Pharma and Healthcare | Nippon India Taiwan Equity |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.8% | 0.0% |
| Semiconductors | 0.0% | 31.5% |
| Electronic Components | 0.0% | 25.1% |
| Healthcare Services | 20.9% | 0.0% |
| Semiconductor Materials & Equipment | 0.0% | 11.8% |
| Electronic Equipment & Instruments | 0.0% | 8.2% |
| Communications Equipment | 0.0% | 5.1% |
| Technology Hardware, Storage & Peripherals | 0.0% | 4.8% |
| Healthcare Equipment & Supplies | 1.5% | 0.0% |
| Consumer Durables | 1.2% | 0.0% |
| Chemicals & Petrochemicals | 0.9% | 0.0% |
The six largest sectors of each fund's stocks, % of the fund.
ITI Pharma and Healthcare vs Nippon India Taiwan Equity: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | ITI Pharma and Healthcare Fund | Nippon India Taiwan Equity Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.89% | 1.08% |
| Base expense ratio (Direct) | 0.58% | 0.80% |
| Total expense ratio (Regular) | 2.59% | 2.36% |
| Base expense ratio (Regular) | 2.10% | 1.92% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare ITI Pharma and Healthcare with
ITI Pharma and Healthcare Fund vs Nippon India Taiwan Equity Fund: Frequently Asked Questions
What is the difference between ITI Pharma and Healthcare Fund and Nippon India Taiwan Equity Fund?
ITI Pharma and Healthcare Fund is a Thematic fund, Nippon India Taiwan Equity Fund is a Thematic fund, run by ITI Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 0.0%. ITI Pharma and Healthcare Fund charges 0.89% a year and Nippon India Taiwan Equity Fund 1.08%.
Which has given higher returns, ITI Pharma and Healthcare Fund or Nippon India Taiwan Equity Fund?
Over 1 year: ITI Pharma and Healthcare Fund +9.43%, Nippon India Taiwan Equity Fund +75.71%. Over 3 years: ITI Pharma and Healthcare Fund +20.30% a year, Nippon India Taiwan Equity Fund +54.78% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, ITI Pharma and Healthcare Fund or Nippon India Taiwan Equity Fund?
ITI Pharma and Healthcare Fund charges less: 0.89% a year against 1.08%. These are the Direct plans' total expense ratios reported to AMFI.
How much do ITI Pharma and Healthcare Fund and Nippon India Taiwan Equity Fund overlap?
0.0%. They hold 0 of the same securities. From each fund's latest monthly portfolio.
Which is riskier, ITI Pharma and Healthcare Fund or Nippon India Taiwan Equity Fund?
On SEBI's riskometer, ITI Pharma and Healthcare Fund is rated Very High and Nippon India Taiwan Equity Fund Very High. Over 3 years, the standard deviation of daily returns was 14.17% and 35.27% a year.
Which is better for SIP, ITI Pharma and Healthcare Fund or Nippon India Taiwan Equity Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹4,46,688 in ITI Pharma and Healthcare Fund (XIRR 12.3% a year) and ₹8,42,956 in Nippon India Taiwan Equity Fund (XIRR 59.7% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both ITI Pharma and Healthcare Fund and Nippon India Taiwan Equity Fund?
Yes. 0.0% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages ITI Pharma and Healthcare Fund and Nippon India Taiwan Equity Fund?
ITI Pharma and Healthcare Fund: Animesh Singh, Nilay Dalal. Nippon India Taiwan Equity Fund: Kinjal Desai.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.